Ambu

Regulatory Filings • Dec 2, 2008

Ambu enters into a final agreement to acquire assets from the US company Sleepmate Technologies – a leading player within sensors for sleep examinations

As announced in company announcement no. 1-2008/09 Ambu entered into a conditional agreement on 4 November 2008 to acquire the assets of the US company Sleepmate Technologies Inc. The terms, which were conditional for the completion of the transaction, have been fulfilled, and the final agreement has been signed today.

As previously announced the purchase price amounts to USD 6.9m and is paid in cash.

Sleepmate Technologies is one of the leading players on the attractively growing US market within diagnostic sensors for Obstructive Sleep Apnea.

As previously announced the acquisition will contribute to a strengthening of Ambu's market position within Neurology, particularly on the US market. It is not expected that the acquisition will contribute considerably to Ambu's revenue and profit in 2008/09.

For further information please contact: Lars Marcher, CEO, phone +45 5136 2490, e-mail lm@ambu.com

Ambu develops, produces and markets diagnostic and life-supporting devices to hospitals and rescue services. Ambu has five business areas: Respiratory Care, Cardiology, Neurology, Training and Immobilization. The most important business areas are Respiratory Care, Cardiology and Neurology, and the most important products in these areas are ventilation products for artificial respiration and single-use electrodes for ECG recordings and neurophysiological examinations. Ambu's products are sold worldwide. Exports account for 98% of sales, and sales are handled via Ambu's foreign subsidiaries or via distributors. Ambu has just over 1,400 employees, of whom approx. 300 work in Denmark and approx. 1,100 abroad.

Ambu A/S

Baltorpbakken 13 DK-2750 Ballerup CVR 63 64 49 19 T+45 7225 2000 F+45 7225 2050 www.ambu.com